Table 1 Summary of the baseline characteristics of the included studies
From: Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
Study (year) | SGLT2i | Population | Patients (SGLT2i/Placebo) (n) | DM/non-DM (SGLT2i, Placebo) (n) | HF/non-HF (SGLT2i, Placebo) (n) | CKD/non-CKD (SGLT2i, Placebo) (n) |
|---|---|---|---|---|---|---|
EMPEROR-REDUCED [6] (2020) | Empagliflozin 10Â mg once daily | HFrEF | 1863/1867 | (927, 926)/NR | (1863, 1867)/(0, 0) | (969, 960)/(893, 906) |
EMPA-REG [2] (2015) | Empagliflozin 10Â mg or 25Â mg once daily | Type 2 diabetes | 4687/2333 | (4687, 2333)/NR | NR/NR | (1196, 605)/(3449, 1718) |
EMPEROR-PRESERVED [27] (2021) | Empagliflozin 10Â mg once daily | HFpEF | 2997/2991 | (1465, 1471)/NR | (2997, 2991)/(0, 0) | (1504, 1484)/(1493, 1505) |
EMPLUSE [20] (2021) | Empagliflozin 10Â mg once daily | acute de novo or decompensated chronic HF | 265/265 | NR/NR | (265, 265)/(0, 0) | NR/NR |
EMPA-KIDNEY [9] (2022) | Empagliflozin 10Â mg once daily | CKD | 3304/3305 | (1525, 1515)/(1779, 1790) | NR/NR | (3304, 3305)/(0, 0) |
DECLARE-TIMI 58 [4] (2009) | Dapagliflozin 10Â mg once daily | Type 2 diabetes | 8582/8578 | (8582, 8578)/(0, 0) | (852, 872)/(7730, 7706) | (606, 659)/(7975, 7919) |
DAPA-HF [5] (2020) | Dapagliflozin 10Â mg once daily | HFrEF | 2373/2371 | (1075, 1064)/(1298, 1307) | (2373, 2371)/(0, 0) | (962, 964)/(1410, 1406) |
DAPA-CKD [8] (2020) | Dapagliflozin 10Â mg once daily | CKD | 2152/2152 | (1455, 1451)/(697, 701) | NR/NR | (2152, 2152)/(0, 0) |
DELIVER [29] (2022) | Dapagliflozin 10Â mg once daily | HFrEF or HFpEF | 3131/3132 | (1578, 1572)/(1551, 1558) | (3131, 3132)/(0, 0) | (1516, 1554)/(1615, 1577) |
CANVAS [3] (2017) | Canagliflozin 300Â mg or 100Â mg once daily | Type 2 diabetes | 5795/4347 | (5795, 4347)/(0, 0) | (803, 658)/(4992, 3689) | NR/NR |
CREDENCE [7] (2019) | Canagliflozin 100Â mg once daily | Type 2 diabetes | 2202/2199 | (2202, 2199)/(0, 0) | (329, 323)/(1873, 1876) | (1297, 1295)/(905, 904) |
SOLOIST-WHF [49] (2021) | Sotagliflozin 200Â mg once daily | Type 2 diabetes | 608/614 | (608, 614)/(0, 0) | (608, 614) | NR/NR |
SCORED [48] (2021) | Sotagliflozin 200 mg once daily | Type 2 diabetes + CKD | 5292/5292 | (5292, 5292)/(0,0) | (1640, 1643)/(3652, 3649) | (5292, 5292)/(0,0) |
VERTIS CV [59] (2020) | Ertugliflozin 5Â mg or 15Â mg once daily | Type 2 diabetes | 5499/2747 | (5499, 2747)/(0,0) | (1288, 671)/(4207, 2074) | (1288, 671)/(4207, 2074) |